Laura Harvey1, Christopher Holley1, Samit S Roy2, Peter Eckman2, Rebecca Cogswell2, Kenneth Liao1, Ranjit John3. 1. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota. 2. Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 3. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota. Electronic address: johnx008@umn.edu.
Abstract
BACKGROUND: Left ventricular assist devices (LVADs) are increasingly used in patients with heart failure. To study the impact of stroke on clinical outcomes after continuous-flow (CF-) LVAD implantation, we evaluated our single-center experience. METHODS: From 2006 to 2013, we implanted the HeartMate II CF-LVAD in 230 patients. We used standard statistical methods to evaluate our results. RESULTS: Of our study group, 185 patients (80.4%) received the CF-LVAD as a bridge to transplantation. Strokes occurred in a total of 39 patients (17%), an incidence rate of 0.064 strokes per person-year: 19 (48.7%) were embolic, and 20 (51.3%) were hemorrhagic. The stroke-free rate at 6 months after HeartMate II implantation was 92.6%, at 12 months, 89.6%, and at 24 months, 86.1%. Baseline demographic characteristics did not differ significantly, except that stroke patients had a lower incidence of coronary artery disease (p = 0.004) and prior cardiac surgery (p = 0.001). We noted a trend toward an increased risk of stroke in patients with CF-LVAD-related infections (p = 0.053). The survival rate in stroke (versus stroke-free) patients at 6 months was 84.6% (versus 84.2%); at 12 months, 71.8% (versus 81.6%); and at 24 months, 53.9% (versus 74.7%; p = 0.0019). During a median follow-up time of 761 days, mortality risk in stroke patients was 2.01 times that of stroke-free patients (hazard ratio = 2.01; p = 0.004). CONCLUSIONS: Stroke while on CF-LVAD support was associated with significant mortality. To reduce the risk of stroke, it is essential to further elucidate risk factors, to optimize anticoagulation, and to further understand the impact of LVAD-related infections.
BACKGROUND: Left ventricular assist devices (LVADs) are increasingly used in patients with heart failure. To study the impact of stroke on clinical outcomes after continuous-flow (CF-) LVAD implantation, we evaluated our single-center experience. METHODS: From 2006 to 2013, we implanted the HeartMate II CF-LVAD in 230 patients. We used standard statistical methods to evaluate our results. RESULTS: Of our study group, 185 patients (80.4%) received the CF-LVAD as a bridge to transplantation. Strokes occurred in a total of 39 patients (17%), an incidence rate of 0.064 strokes per person-year: 19 (48.7%) were embolic, and 20 (51.3%) were hemorrhagic. The stroke-free rate at 6 months after HeartMate II implantation was 92.6%, at 12 months, 89.6%, and at 24 months, 86.1%. Baseline demographic characteristics did not differ significantly, except that strokepatients had a lower incidence of coronary artery disease (p = 0.004) and prior cardiac surgery (p = 0.001). We noted a trend toward an increased risk of stroke in patients with CF-LVAD-related infections (p = 0.053). The survival rate in stroke (versus stroke-free) patients at 6 months was 84.6% (versus 84.2%); at 12 months, 71.8% (versus 81.6%); and at 24 months, 53.9% (versus 74.7%; p = 0.0019). During a median follow-up time of 761 days, mortality risk in strokepatients was 2.01 times that of stroke-freepatients (hazard ratio = 2.01; p = 0.004). CONCLUSIONS:Stroke while on CF-LVAD support was associated with significant mortality. To reduce the risk of stroke, it is essential to further elucidate risk factors, to optimize anticoagulation, and to further understand the impact of LVAD-related infections.
Authors: Joshua Z Willey; Michael V Gavalas; Pauline N Trinh; Melana Yuzefpolskaya; A Reshad Garan; Allison P Levin; Koji Takeda; Hiroo Takayama; Justin Fried; Yoshifumi Naka; Veli K Topkara; Paolo C Colombo Journal: J Heart Lung Transplant Date: 2016-03-30 Impact factor: 10.247
Authors: Chinenye O Usoh; Saadia Sherazi; Barbara Szepietowska; Valentina Kutyifa; Scott McNitt; Anna Papernov; Meng Wang; Jeffrey D Alexis Journal: Ann Thorac Surg Date: 2018-03-22 Impact factor: 4.330
Authors: Joshua Z Willey; Amelia K Boehme; Francesco Castagna; Melana Yuzefpolskaya; A Reshad Garan; Veli Topkara; Paolo C Colombo Journal: Curr Hypertens Rep Date: 2016-02 Impact factor: 5.369
Authors: John C O'Horo; Omar M Abu Saleh; John M Stulak; Mark P Wilhelm; Larry M Baddour; M Rizwan Sohail Journal: ASAIO J Date: 2018 May/Jun Impact factor: 2.872